Abstract
Lercanidipine is a calcium-channel blocker used in the treatment of mild to moderate hypertension. It is administered in daily doses of 10 to 20 mg.
As opposed to other dihydropyridine representatives, it is characterised by lower occurrence rate of undesirable effects as was demonstrated in a number of clinical trials, especially in terms of reduced rates of perimalleolar oedemas